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third degree). The patient with a third degree was not treated for
the LS during the first pregnancy, and there was some delayed
healing. There were no issues with her second delivery when LS
was quiescent. No patients developed LS in obstetric scars.
In a series of 40 patients studied for the effect of the oral con-
traceptive on LS, four became pregnant and reported complete
remission of disease during pregnancy.3 A study of 33 pregnan-
cies in 29 patients with vulval LS reported 27 spontaneous vagi-
nal births, two instrumental deliveries and 4 LSCS. Only one
non-compliant patient required a section due to LS-related scar-
ring.4 One patient developed LS in a perineal scar. Two women
with newly diagnosed LS and who delivered by normal sponta-
neous vaginal delivery without problems have been reported.5
The proportion of women with an intact perineum at delivery
was 9.6% in nulliparae and 31.2% in multiparae.6 In our popula-
tion with LS, 10/21 nulliparae had tears and 9/21 had epi-
siotomies; therefore, there was no increased incidence of
perineal tears and episiotomies compared to the general popula-
tion. No patients reported sexual dysfunction during follow-up
of up to 4 years in many cases.
There is conflicting literature on the requirements for TCS
during pregnancy and by extrapolation the severity of LS during
pregnancy. There was no significant change in the TCS require-
ments in one study,4 but in others the effect was variable.7,8 In
our cohort, 55% patients had the same TCS requirements during
pregnancy but 45% decreased their use suggesting improvement
in their LS.
In conclusion, LS does not worsen during pregnancy and can
improve. When the disease is well controlled, there is no contra-
indication to vaginal delivery and women can be reassured about
this.
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and molecular genetic analysis
of a large Russian family with a
synonymous p.Ser267=
(c.801A>G) splice site mutation
Editor
X-linked hypohidrotic ectodermal dysplasia (XLHED) is the
most common form of ectodermal dysplasias.1 Mutations in the
EDA gene are the cause of XLHED.2 This study describes a large
Russian family with XLHED (Fig. 1).
The proband’s examination revealed a large forehead with
prominent supraorbital ridges and forehead bumps, wide cheek-
bones, small saddle-shaped nose with hypoplastic alae nasi, nar-
row and short maxillary regions, slightly deformed ears. The
hair, eyebrows and eylashes were light-coloured, sparse and brit-
tle. The skin was dry and pale. However, according to the
mother, the proband had good heat tolerance. Examination
revealed hypoplastic nipples, but nail structure was normal. The
proband was susceptible to respiratory infections. Intraoral
examination showed complete adontia. The mouth mucosa was
pale, with noticeable hypersalivation. The maxilla and mandi-
bula were hypoplastic with underdeveloped alveolar processes.
X-ray orthopantomography revealed four rudimentary baby
teeth and two rudimentary permanent central maxilla incisors.
The proband’s EDA gene coding sequence and exon–intron
junction analysis by Sanger sequencing revealed a synonymous
p. Ser267= (c.801A>G) variant in exon 7. This variant was not
present in the dbSNP or the Genome Aggregation Database but
was described in HGMD (CS1614178) by Wohlfart et al.3 The
c.801A>G variant segregates with the disease: it was detected in
all affected males in hemizygous state, in females – in heterozy-
gous state and was not detected in a healthy blood relative
(Fig. 1). The probability of the simultaneous inheritance of the
XLHED and the revealed EDA gene variant in this family being a
coincidence is about 0.01%.
In silico Human Splicing Finder and ESE finder analysis
revealed that c.801A>G variant could break the site of an exonic
splicing enhancer (ESE) and create a new exonic splicing silencer
(ESS), resulting in pre-mRNA splicing alteration. However,
three other splicing tools – BDGP, SplicePort and NetGene2 –
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Figure 2 Functional pathogenicity evidence of the c.801A>G variant in the EDA gene. (a) RT-PCR analysis of EDAmRNA structure
revealed that the c.801A>G variant leads to exon 7 skipping (Δ7). On the top, the scheme of analysed EDA locus is depicted. PAGE elec-
trophoregram shows Δ7 EDAmRNA isoform in both patients’ samples (III.3, V.5), wild-type (WT) and Δ7 isoforms in the mother’s sample
(IV.6) and WT isoform in the father’s sample (IV.5). Sanger sequences of corresponding PCR products are shown below. (b) Results of
minigene assay. The scheme of minigene cloning and analysis is depicted above. Agarose gel electrophoregram of RT-PCR fragments
generated from minigene-spliced RNA of wild-type (WT) and mutant (MUT) constructions are depicted below. The empty rectangle repre-
sents the artificial exon created by a cryptic splice acceptor site of EDA intron 7 and cryptic splice donor site of the vector intron. Analysis
revealed that mutant construction produces only transcripts with exon 7 sipping, while wild-type construction shows its inclusion.
Figure 1 Pedigree of a Russian family with ectodermal hypohidrotic dysplasia. Squares and circles represent males and females,
respectively. The black symbol indicates the affected member; the grey symbol, the female carriers; and the open symbols, the unaf-
fected members. The patient above the arrow is the proband of this family. mut – p.Ser267= (c.801A>G) variant in the EDA gene. N – cor-
responds with EDA reference sequence. Numbers under the genotype of female carriers indicate the percentage of X chromosome
inactivation: 92% – of the mutant X chromosome, 8% – of the intact X chromosome (e.g. proband’s mother IV.6). The obtained data cor-
relate with the severity of the clinical findings seen in female carriers. *mild clinical manifestations: slight dryness of the skin. **moderate
clinical manifestations: micro and hypodontia, dry skin. ***severe clinical manifestations: hypotrichosis, hypodontia, hypohidrosis, dry
skin with atopic eczema, poor mammary gland development, difficulty breastfeeding, increased susceptibility to infections.
© 2019 European Academy of Dermatology and VenereologyJEADV 2019, 33, e437–e495
Letters to the Editor e469
did not predict any splicing changes. To validate the influence of
the synonymous variant c.801A>G on EDA pre-mRNA splicing,
we performed reverse transcription with nested PCR analysis of
total RNA obtained from patients’ peripheral blood mononu-
clear cells (Fig. 2a). RT-PCR analysis revealed the shorter iso-
form of EDA mRNA with exon 7 skipping (Δ7) in the patients’
samples, while the unaffected father had only wild-type (WT)
isoform and the mother had both isoforms. To additionally
prove the pathogenic role of the investigated variant, we per-
formed a minigene splicing assay (Fig. 2b).4
The result confirmed that the EDA c.801A>G variant leads to
exon 7 skipping. The absence of the exon 7 in the structure of
mature EDA mRNA leads to a frame shift resulting in a trun-
cated non-functional EDA protein p.(D265Gfs7*), lacking part
of the conserved motifs in the TNF-related domain and the
whole cysteine-rich C-terminal domain.5 According to variant
interpretation criteria,6 the c.801A>G variant should be consid-
ered pathogenic: PVS1, PS3, PM1, PM2, PP3 and PP5. Thus, an
independent comprehensive analysis of the synonymous
p.Ser267= (c.801A>G) EDA gene variant’s clinical significance in
a large Russian family showed its critical splicing effect on
ectodysplasin-A synthesis.
X-linked hypohidrotic ectodermal dysplasia shows incom-
plete penetrance in females. The probability of recognizing a
female carrier via clinical examination is evaluated to be 60–
70%.5 The incomplete penetrance in female carriers can be
caused by unequal X chromosome inactivation. The unequal
X chromosome inactivation pattern analysis was performed
for female carriers.7 It is worth noting that two females in the
studied family are confirmed as asymptomatic mutation carri-
ers while other female relatives have variable HED signs
(Fig. 1). The obtained data confirm the theoretical suggestions
about XLHED pathogenic mechanisms in female carriers:
there is an explicit correlation between the disease severity
and the non-random X chromosome inactivation level in the
studied family.
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within a large Midwestern U.S.
patient population from the
Research on Adverse Drug
events And Reports program
Editor
Tenofovir disoproxil fumarate (TDF) combined with emtric-
itabine (FTC) for HIV pre-exposure prophylaxis (PrEP; FDA
approval 07/2012) has been shown to dramatically decrease HIV
acquisition rates in high-risk populations.1–4 TDF-FTC is also
used as part of multidrug combination antiretroviral (cART)
regimens for treatment of HIV(+) patients (FDA approval 08/
2004). When TDF-FTC is used as part of cART, cutaneous
adverse events (cAEs), including serious cAEs, have been well-
reported.5,6 However, no cAEs were reported in premarketing
trials for those exposed to PrEP.1–3,7 The aim of this study is to
determine the incidence of cAEs for TDF-FTC in HIV() per-
sons compared to HIV(+) persons receiving TDF-FTC as a com-
ponent of cART.
Using RADAR methodology,8 retrospective data were extracted
(2001—2017) from a medical record database for a large urban,
Midwestern U.S. patient population of >6 million patients for
persons prescribed TDF-FTC for HIV prevention (ICD9: V01,
79; ICD10: Z20.6), and compared to those with HIV/AIDS
infection (ICD9: V08, 042; ICD10: Z21, B20-24) who were
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